Table 2.
Response to CT and Relapse Rates in the Three DLBCL Patient Groups
| Variable | No. of Patients (%)
|
p
|
||||
|---|---|---|---|---|---|---|
| Cases Given AVT (A) | Cases Never Given AVT (B) | Controls (C) | All Three Groups* | (A v B)† | (B v C)* | |
| Response to first-line CT‡ | N = 26 | N = 36 | N = 198 | 0.15 | 0.11 | 0.05 |
| CR or PR | 22 (85) | 24 (67) | 165 (83) | |||
| Progressive disease | 4 (15) | 12 (33) | 33 (17) | |||
| Relapse after first CR, PR‡ | N = 22 | N = 24 | N = 163 | 0.88 | 0.73 | 0.66 |
| Yes | 9 (41) | 11 (46) | 66 (40) | |||
| No | 13 (59) | 13 (54) | 97 (60) | |||
| Oncologic outcome at last follow-up‡ | N = 26 | N = 36 | N = 197 | 0.18 | 0.06 | 0.09 |
| CR or PR | 19 (73) | 18 (50) | 135 (69) | |||
| Progressive disease | 7 (27) | 18 (50) | 62 (31) | |||
AVT indicates antiviral therapy; CT, chemotherapy; CR, complete response; and PR, partial response.
*
Generalized estimating equations and logit link function.
†
Pearson chi-square test.
‡
Ten patients who received AVT after CT were not included.